Vivesto — Share Issue/Capital Change 2011

Oct 25, 2011

2011-10-25

PRESS RELEASE

Directed new share issue successfully completed – nxt2b new major shareholder

• Directed new share issue of SEK 48 million successfully completed
• nxt2b (Nexttobe AB), an investment company owned by Bengt Ågerup, has subscribed for shares to an amount of SEK 30 million
• Including an acquisition of existing shares from the major shareholder, nxt2b will become the second largest shareholder with 10.1% of the shares and votes

Oasmia Pharmaceutical AB (publ) ("Oasmia" or the "Company") has successfully raised SEK 48 million in a new share issue directed to nxt2b, subscribing for shares to an amount of SEK 30 million, and other investors, subscribing for shares to an amount of SEK 18 million.

The directed new share issue strengthens Oasmia's financial position for the continued clinical development of its product portfolio, and improves the Company's position in ongoing and upcoming discussions with existing and potential new sales partners, providing more flexibility in the timing of such partnerships. The directed new share issue will also provide Oasmia with a new major shareholder with long and rigorous experience from the healthcare industry.

The directed new share issue was carried out with deviation from the shareholders' preferential rights and in accordance with the AGM's resolution, on September 30, 2011, to authorize the Board of Directors in Oasmia to, at one or several occasions until the next AGM issue new shares. The new share issue concerned 5,161,290 new shares, increasing the number of shares outstanding from 52,079,341 to 57,240,631. The subscription price was SEK 9.30 per new share.

In addition to subscribing for shares in the directed new share issue, nxt2b has acquired 2,555,500 existing shares from Oasmia's main shareholder, Alceco International S.A. Following the directed new share issue and the acquisition of existing shares nxt2b becomes the second largest shareholder in Oasmia with a total of 10.1% of the shares and votes, while Alceco International S.A.'s shareholding will decrease to 46.2%.

• It is with great pleasure that I welcome Mr. Bengt Ågerup and nxt2b as a shareholder and I am convinced that this is the start of a close collaboration, says Julian Aleksov, CEO of Oasmia.

• We are excited about the opportunity to invest in Oasmia. The Company has a very interesting product portfolio with several promising product candidates within both human and veterinary medicine. With our long experience from the healthcare industry we hope to be able to support the management in the development of the Company with both expertise and new relationships", says Bengt Ågerup of nxt2b.

• We are pleased to see great interest in Oasmia and welcome nxt2b and other investors as new shareholders. The share issue strengthens our financial position and provides an improved position with regard to ongoing and upcoming discussions with sales partners", says Joel Citron, Chairman of the Board in Oasmia.

Carnegie Investment Bank AB has acted as financial advisor to Oasmia.

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well established cytostaticswhich, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents. The company was regi stered in 1999 and is located in Uppsala, Sweden.

About nxt2b

nxt2b is a privately owned investment company started in 2011 by the Swedish entrepreneur Bengt ƒgerup. nxt2b focuses on growth equity investments in healthcare, medical devices and specialty pharmaceutical companies but also invests in technology and consumer companies. With its structure nxt2b is able to make fast decisions on any investment opportunity and has invested in more than 15 companies. nxt2b supports its portfolio company management teams not only financially but also with entrepreneurial experience to build fast growing, market leading companies.

Press contact for Oasmia is Maria Lund"n, telephone: +46 (0) 18 50 54 40 Press contact for nxt2b is Alexander Kotsinas, telephone+46 (0)73 500 11 11

For more information, please contact: Maria Lund"n, Head of Public Relations, Oasmia Pharmaceutical AB. E-mail: press@oasmia.comPhone: +46 (0) 18 50 54 40. German co ntacts: Dr. S…nke Knop, Peggy Kropmanns, edicto GmbH, Frankfurt,Germany. E-Mail: oasmia@edicto.de, Phone : +49 (0) 69 90 55 05 51. Information is also available at www.nasdaqomxnordic.comwww.boerse-frankfurt.de

€Oasmiais required under the Financial Instruments Trading Act to make the information in this press release public. The information was submittedfor publicationat 08.25CET onOctober 25.•